



CAR-T therapy access: The reality in numbers

World Cancer Day
February 4th, 2026






Despite innovation, the number of patients treated with CAR-T therapy remains low.

Globally, how many patients with blood cancer have received one of the 8 CAR-T products* to date?

*EMA/FDA approved



Despite its potential, CAR-T therapy has reached only ~45.000 patients globally by Q3 2025.





CAR-T therapy is available in Europe, the US, Canada, Australia, Japan, India, and China*.


How many patients were treated in Europe?

Ge 2024, Blood

*CAR-T therapy is available in mostly high-income countries in North America, Europe, Asia, and the Pacific, as well as selected middle-income countries like China, Brazil, and India. Although more challenging, it is available in some African countries e.g. South Africa



EBMT registered 4.757 new CAR-T patients in Europe in 2025



EBMT registry, 2025, commercial, investigational, and unknown registries cumulated



What does access
look like across
Europe?





On average, ~18% of eligible patients received CAR-T therapy across Europe* in 2024.

United Kingdom

Germany

15

17

France

30

11

18

Spain

Italy


*eligible patients in %
IQVIA 2025



Which European
countries provide access
to CAR-T therapy?



17.220 CAR-T patients were reported across 24 European countries by 2026





Innovative concepts need to overcome current hurdles, such as:



Capacity constraints of centralized and decentralized manufacturing



Referral pathways



Reimbursement & funding



Geographic disparities



Data. Dialogue. Action.

Changing patient
access requires
collaboration.
That's where
EASYGEN starts.

What are your thoughts about access?
Get involved and comment below

